Clinical response and survival following pomalidomide/dexamethasone in Len-refractory myeloma. Patients were randomized to therapy with pomalidomide at 2 mg/day on a 28/28-day continuous schedule (n = 19; cohort 1), or 4 mg/day on a 21/28-day intermittent schedule (n = 20; cohort 2). All patients received Pom alone for cycle 1 and with weekly dexamethasone with cycle 2 and beyond. (A) Waterfall plot of maximal reduction in measurable disease. (B) Kaplan-Meier plot comparing event-free survival in the 2 cohorts. (C) Kaplan-Meier plot comparing overall survival in the 2 cohorts.